

Analysis of T Cell Receptor Repertoire of Muscle-infiltrating T Lymphocytes in Polymyositis

Restricted V α / β Rearrangements May Indicate Antigen-driven Selection

Renato Mantegazza,* Francesca Andretta,* Pia Bernasconi,* Fulvio Baggi,* Jorge R. Oksenberg,[‡] Ornella Simoncini,* Marina Mora,* Ferdinando Cornelio,* and Lawrence Steinman[‡]

*Department of Neuromuscular Diseases, C. Besta National Neurological Institute, Milan, 20133 Italy; and [‡]Department of Neurology and Neurological Sciences, Stanford University Medical Center, Stanford, California 94305

Abstract

Polymyositis is an inflammatory myopathy characterized by mononuclear cell infiltration of muscle tissue. Myocytotoxic T lymphocytes have been recognized in the infiltrates, but the muscle antigen, target of the immune attack, has not been identified. Molecular characterization of the variable regions of T cell receptors (TCRs) on the infiltrating lymphocytes can be expected to provide insights into the pathogenic process. The V α / β TCR repertoire was investigated by RNA-PCR in muscle biopsies from 15 polymyositis patients and 16 controls (6 Duchenne muscular dystrophy and 10 with no inflammatory or dystrophic myopathy). A variety of rearranged variable TCR genes was found in polymyositis, V α 1, V α 5, V β 1, and V β 15 being the most common (present in 60–100% of patients). In Duchenne muscular dystrophy patients TCR V α or β rearrangements were found although no restriction was observed; no rearrangements were found in muscles from the other controls. Sequence analysis revealed the presence of the J β 2.1 region in 90% of the V β 15 clones studied, no random N additions in the diversity region, and a common motif within the CDR3 region. These results suggest that selection of muscle-infiltrating T lymphocytes is antigen driven in polymyositis. (*J. Clin. Invest.* 91:2880–2886.) Key words: polymyositis • Duchenne muscular dystrophy • T cell receptor • T lymphocyte • polymerase chain reaction

Introduction

Polymyositis (PM)¹ is an inflammatory myopathy in which intense mononuclear cellular infiltration leads to the degeneration of the muscular fibers (1–3). The cellular infiltrate has

been extensively characterized by immunocytochemistry and mainly consists of T lymphocytes, macrophages, and, to a lesser extent, B cells and natural killer cells (4, 5). The T cell component is predominantly CD8⁺ lymphocytes with cytotoxic activity (6–8). Increased expression of MHC class I and II in muscle (9–11) and of lymphokines (IL-1 α , IL-2, IFN- γ) in serum (12, 13) have also been reported. These findings point to immune activation towards an as yet unknown muscle antigen. The vast majority of peripheral blood CD4⁺ and CD8⁺ T lymphocytes express α / β T cell receptors (TCR), but the TCR repertoire of PM-specific T cell infiltrate is not known. Recently, a subset of γ / δ T lymphocytes was demonstrated to be infiltrating the muscle of one PM patient (14) and the molecular characteristics of their TCR described (15). We report here on the characterization of the cellular infiltrates from muscles of 15 PM patients, including α / β TCR usage at the site of muscle fiber degeneration, since this information would provide indications on T cell clonality in the site of lesion.

Methods

Muscle samples obtained by needle biopsy from 15 PM patients (referred to as 1–15), were frozen and stored in liquid nitrogen. PM diagnosis was on the basis of clinical signs of weakness, elevated serum creatine kinase, and myopathic changes in the electromyogram (16). Dermatomyositis was ruled out by lack of skin rash. No symptoms or signs of associated neoplasm, collagen, or vascular diseases were present. For control purposes, muscle samples from 10 subjects without inflammatory myopathy or muscular dystrophy, and from 6 Duchenne muscular dystrophy (DMD) patients were also analyzed. Portions of the same muscle biopsy were used for both immunocytochemical and molecular analyses.

Immunocytochemistry. Cellular infiltrates were characterized by immunocytochemistry on acetone-fixed 4–6- μ m thick cryosections of muscle biopsies. The following Abs were used: anti-CD3 (Dako, Copenhagen, Denmark), anti-CD4, anti-CD8, anti-CD19, anti-CD14 (Becton Dickinson, Mountain View, CA), and anti- α / β TCR (Identi T[®] β F1, β -chain specific; T Cell Sciences, Inc., Cambridge, MA). All Abs were mouse mAbs, except anti-CD3 which was an affinity-purified rabbit polyclonal Ab. The mouse mAbs were detected using rhodamine-conjugated goat anti-mouse IgG; the rabbit Ab was detected using biotinylated goat anti-rabbit IgG and by fluorescein-isothiocyanate-labeled streptavidin. From sections stained with peroxidase-conjugated secondary Abs, mAb-positive cell frequencies were counted and statistical analysis was performed as described elsewhere (5).

TCR repertoire analysis. Analysis of the TCR repertoire used the RNA-PCR procedure (17). The common reverse primers specific for the α and β C regions, and family-specific V region forward primers (V α 1–18, and V β 1–20) were used (18). Total RNA was extracted by

Address correspondence to Renato Mantegazza, M.D., Department of Neuromuscular Diseases, C. Besta National Neurological Institute, Via Celoria 11, Milan, 20133 Italy.

Received for publication 20 February 1992 and in revised form 5 February 1993.

1. Abbreviations used in this paper: DMD, Duchenne muscular dystrophy; EB, ethidium bromide; PM, polymyositis; TCR, T cell receptor.

J. Clin. Invest.

© The American Society for Clinical Investigation, Inc.

0021-9738/93/06/2880/07 \$2.00

Volume 91, June 1993, 2880–2886

the single step guanidinium-thiocyanate-phenol-chloroform method (19) on 10–60 mg of frozen muscle. cDNA for PCR amplification was prepared using reverse transcriptase according to standard protocol (17). The resulting cDNA mixture was used directly in PCR amplification with the addition of 50 pmol of forward and reverse primers, 1× PCR buffer and 1 U *Taq* polymerase (Perkin-Elmer Corp., Norwalk, CT). 30 cycles of the following profile were performed on automated DNA thermocycler: 95°C denaturation for 1 min, 55°C annealing for 1 min, 72°C extension for 1 min. Aliquots of the amplified products were electrophoresed on 4% NuSieve-Agarose (FMC Corp., Rockland, ME) (3:1, wt/wt) gels stained with ethidium bromide (EB). cDNA from a mixed lymphocyte reaction of healthy individuals was used to amplify all $V\alpha$ and $V\beta$ families and served as a positive control.

“Mini” Southern blot and internal probing. Amplified products were electrophoresed on a mini-gel apparatus (Bio-Rad Laboratories, Richmond, CA) in 2% NuSieve-Agarose (FMC Corp.) (3:1, wt/wt) gel stained with EB. Gels were soaked in a denaturing solution (0.5 M NaOH, 1.5 M NaCl) for 30 min, then in a neutralizing solution (0.5 M Tris-HCl, 1.5 M NaCl, pH 7.0) for 30 min, with shaking at room temperature. The gels were blotted onto Genescreen Plus nylon filters (DuPont Instruments, Wilmington, DE) for 2 h. The DNA was covalently bound to the nylon membranes by ultraviolet cross-linking (550 μ J) using a Stratalinker apparatus (Stratagene Inc., La Jolla, CA). Membranes were boiled in 1% SDS for 5 min, briefly dried, and prehybridized in 5× sodium chloride-sodium phosphate-ethylenediaminetetraacetate (SSPE)/5× Denhardt’s solution/100 μ g/ml salmon sperm DNA/0.1% SDS at 42°C for 10 min. C region internal horseradish peroxidase (HRP)-labeled probe ($C\alpha$ 5′ HRP-CAGAACCTGAC-CCTGCCGTGTAC-3′ and $C\beta$ 5′ HRP-AGCGACCTCGGTTGG-GAACAC-3′) was added and hybridized for 1 h at 42°C. After hybridization, filters were washed once with 1× SSPE + 1% SDS for 15 min, then in 0.1× SSPE + 1% SDS for 5 min, and lastly in PBS for 10 min, at room temperature. The amplified TCR products were detected with the enhanced chemiluminescence gene detection kit (Amersham International, Amersham, UK), which uses chemiluminescence to reveal hybridized products; developing procedures were performed according to manufacturer’s instructions, and HYPERfilm-enhanced chemiluminescence detection films (Amersham International, Amersham, UK) were developed after 2–10 min.

Unique restriction site analysis. $V\alpha 1$, $V\alpha 5$, $V\beta 1$, and $V\beta 15$ were also checked for the appropriate restriction pattern by unique site restriction analysis. The PCR products were extracted from minigels and purified using GeneClean II kit (BIO 101, Inc., Vista, CA). They were used as templates for PCR reamplification in which forward and reverse primers were contained within the V sequence region of the corresponding α or β TCR families (see Fig. 4 legend for primers and PCR profile). Aliquots of the reamplified products were digested to reveal the presence of unique restriction sites. The presence of expected size bands was observed on 4–6% of EB-stained agarose gels (see Fig. 4 for restriction endonucleases used and size of bands in each TCR PCR product).

TCR $V\alpha$ and $V\beta$ assignment in PM patients. Specific $V\alpha$ and $V\beta$ TCR rearrangements in any individual were considered detected only when the band observed in the EB gel was confirmed on the mini-blot.

Sequence analysis. $V\alpha 1$, $V\alpha 5$, $V\beta 1$, and $V\beta 15$ amplification products from the mixed lymphocyte reaction were blunt-end cloned into the SmaI site of pGEM 7ZF(–) (Promega Corp., Madison, WI) and transformed into JM 109 *Escherichia coli* strain (Promega Corp.); a total of eight randomly chosen colonies were sequenced by the dideoxy chain-termination method (20), using the Deaza G/A ¹⁷Sequencing kit (Pharmacia, Uppsala, Sweden). cDNA of two PM patients (1 and 5) was amplified by PCR using $V\beta$ 15 and $C\beta$ primers containing EcoRI and HindIII restriction sites, respectively. The PCR product was purified from 0.6% low melting agarose gel by phenol-chloroform extraction and digested sequentially with EcoRI and HindIII (Boehringer Mannheim GmbH, Mannheim, Germany). After purification by Centricon 100 (Amicon, Beverly, MA), the product was cloned into EcoRI-HindIII digested pGEM 7ZF(–) and transformed into JM 109 *E. coli* strain. Plasmid DNA samples were prepared from white colo-

nies and analyzed by digestion with DraII, which cleaves a unique restriction site contained in the $C\beta$ region but not present in the plasmid. Positive colonies were sequenced by the dideoxy chain-termination method with the Deaza G/A ¹⁷Sequencing kit. Nucleotide sequences were analyzed using Gene Works 2.2 software (IntelliGenetics, Mountain View, CA). The amino acid sequences were aligned to the sequence of the clone ATL 21, known to be $V\beta 15$ (21).

Results

The cell infiltrates of PM patients were first characterized immunocytochemically: T lymphocytes ($CD3^+$ cells), macrophages ($CD14^+$ cells) were the major constituents while rare B lymphocytes ($CD19^+$ cells) were found. Fig. 1 exemplifies the immunocytochemical findings from a PM patient: panels *a*, *c*, and *e* display anti- $CD3$ (pan T) staining, panels *b*, *d*, and *f* anti- α/β TCR, anti- $CD8$ (cytotoxic) and anti- $CD4$ (helper) staining, respectively. All the $CD3^+$ T lymphocytes observed in PM patients’ muscles expressed α/β TCRs on their surface. The relative proportions of CD antigen positive cells in the endomysium, perimysium, and perivascular sites were also determined (Table I). The proportion of $CD8^+$ lymphocytes was significantly greater at endomysial (72%) than perimysial (46%) and perivascular (43%) sites. $CD4^+$ lymphocytes were correspondingly reduced in endomysium (28%), while perimysially and perivascularly they constituted 55 and 58% of the cellular infiltrate, respectively. Furthermore, B lymphocytes were reduced in endomysium (1%) compared to perivascular sites (5%). No significant differences in the proportions of $CD3$ - or $CD14$ -positive cells were observed at different muscle tissue sites.

Immunocytochemical analysis of DMD muscles revealed the presence of mononuclear cell infiltrates, but the CD subsets investigated were distributed relatively uniformly throughout the muscle tissue (data not shown). Cellular infiltrates were not observed in any of the control samples (data not shown).

To characterize the T cells associated with the site of muscle damage in PM, RNA-PCR was used to analyze rearranged genes in the TCRs from PM patients’ muscles. The TCR family-specific primers were tested on cDNA from a mixed lymphocyte reaction for control purpose: all $V\alpha$ and $V\beta$ families were specifically amplified (Fig. 2). Transcripts of the following rearranged α and β TCR genes were obtained from PM patient muscles: $V\alpha 1$, 2, 3, 5, 7, 12, 13, 14, 16, 17, and $V\beta 1$, 3–8, 11–15, 17, and 20 (Table II). Four TCR V gene rearrangements occurred with high frequency in the muscles of PM patients: $V\alpha 1$, 11/15 (73.3%); $V\alpha 5$, 9/15 (60%); $V\beta 1$, 13/15 (86.6%); $V\beta 15$, 15/15 (100%). None of these TCR families were expressed in the controls where only $V\alpha$ 12 and 14 rearrangements were amplified (see Table II). In DMD muscle biopsies the following TCR families were rearranged: $V\alpha$ 1–3, 5, 6, 11–13, 16, 17; $V\beta$ 1–10, 12–16, 18, 19, 20.

The $V\alpha$ - $C\alpha$, and $V\beta$ - $C\beta$ amplifications, specific for the various TCR V gene families, migrated on the gels to the predicted molecular weight positions. Fig. 3 shows an example of PM patients PCR amplification and mini Southern blot: $V\alpha 1$ is at ~ 470 bp, $V\alpha 5$ at ~ 450 bp, $V\beta 1$ at ~ 230 bp, and $V\beta 15$ at ~ 210 bp. The TCR internal probes correctly recognized TCR but not actin.

The $V\alpha 1$, $V\alpha 5$, $V\beta 1$, and $V\beta 15$ PCR products were subsequently reamplified with the corresponding forward primer and an α or β family-specific reverse primer on the 3′ end of the




Figure 1. Immunocytochemistry of PM patient muscle. In *a*, *c*, and *e* the CD3 staining is shown and paired to α/β TCR (*b*), CD8 (*d*), and CD4 (*f*) respectively. Arrowheads indicate cells staining with anti-CD3 monoclonal antibody and negative for anti-CD8. All the cells detected by anti-CD3 were also detected by the anti-TCR- β chain antibody, whereas only a few were positive for anti-CD4.

TCR V region. Fig. 4 illustrates samples of these reamplifications from different patients. Unique site restriction analysis demonstrated that the PCR products were as expected: V-V α 1 digested with MboI shows the expected bands at 114 and 180

bp; V-V α 5 digested with MboI shows the expected bands at 88 and 147 bp; V-V β 1 digested with HinfI shows the expected bands at 27 and 57 bp; V-V β 15 digested with MaeI shows the expected bands at 39 and 50 bp.

Table I. Analysis of Cellular Infiltrates in Muscle of Polymyositis

Marker	Perimysial cells	Endomysial cells	Perivascular cells
CD3	46.7 \pm 19.4	57.6 \pm 13.3	63.7 \pm 9.9
CD8	46.1 \pm 11.8	72.0 \pm 5.0*	43.1 \pm 11.7
CD4	54.7 \pm 11.3	28.2 \pm 5.5 [‡]	57.5 \pm 11.8
CD14	47.1 \pm 17.7	41.4 \pm 12.6	30.1 \pm 8.4
CD19	6.2 \pm 6.4	1.1 \pm 1.3 [§]	5.5 \pm 3.6

Distribution of mononuclear cells in different muscle compartments. All values are expressed as percentage of CD-positive cells, according to reference 5, with minor modifications. Statistical evaluations were performed by a two-tailed *t* test.

* Endomysial vs perimysial *P* = 0.0001, endomysial vs perivascular *P* = 0.0001;

[‡] Endomysial vs perimysial *P* = 0.0001, endomysial vs perivascular *P* = 0.0001;

[§] Endomysial vs perivascular *P* = 0.003.

V β 15 was observed in all the PM patients examined, it was therefore chosen for sequencing. The V β 15 PCR products, amplified from cDNA with primers containing ad hoc restriction sites, were subcloned. Eight colonies from patient 1 and two from patient 5 were sequenced and compared at both the DNA and amino acid level (Table III): amino acid substitutions were minor and the clones were highly homologous. The sequences of the variable regions overlapped to the V β 15⁺ATL 21 clone. Moreover, 9 of the 10 clones (90%) had the same J β 2.1 region. Within the CDR3 portion of J β 2.1 (see Table III) in the TCR β chain, a consensus motif S-EQF was recognized. In the N-D-N region (first half of the CDR3 region) 4 D (Asp) or 2 E (Glu) were found as first amino acid, followed by 5 L (Leu). These data define the sequence D(or E)L-S-EQF, which is a common motif of the CDR3 region of our V β 15⁺ clones.

Discussion

Lymphocyte infiltration of muscle is characteristic of PM and may be intense (1, 4–8); furthermore, activated T cells, mainly of the cytotoxic (CD8⁺) phenotype (6–8), have been demon-




Figure 2. Positive controls for $V\alpha$ and $V\beta$ TCR families amplifications. The EB-stained 4% agarose gels and the corresponding dot-blots of the PCR products are shown. Dot-blot hybridization was performed with the internal probes and the methods described in the text. The positive control (+C) for TCR α chain is the full length cDNA pGA5, shown to be $V\alpha 12$; for the β chain we used cDNA from a cytotoxic antimelanoma clone known to be $V\beta 8$ (a gift from Dr. M. L. Sensi, National Cancer Institute, Milan). β -actin is a 234-bp product amplified with the following primers: F 5'-GTGGGCCGCTCTAGGCACCA-3', R 5'-CGGTTGGCCTTAGGGTTCAGGGGGG-3'.

strated in the muscles of PM patients, and it may be supposed that these cells are intimately involved in PM pathogenesis, either directly by means of perforin/granzyme A (22) or through release of cytotoxic lymphokines (23). The antigen target of autoimmune attack in PM has not been identified. Viruses have suspected to be involved in the immune-mediated mechanisms of PM; however recent findings have shown absence of candidates viral genomes in muscle of patients affected by inflammatory myopathies (24, 25).

Our study has shown the presence of $CD3^+$ (pan T), $CD8^+$ (cytotoxic T cells), $CD4^+$ (helper T cells), and $CD14^+$ (macrophages) cells in the cellular infiltrate of PM muscles. $CD19^+$ (B cell) lymphocytes were also present, but in smaller numbers. These results are similar to those of other authors (4-8). Additionally, we found that the distribution of lymphocyte subsets within the muscle compartments was not homogeneous: the proportion of $CD8^+$ cells in endomysium was significantly greater ($P = 0.0001$) than in the perimysium or surrounding

the perivascular sites; while both $CD4^+$ lymphocytes ($P = 0.0001$) and $CD19^+$ ($P = 0.003$) were reduced in the same district (Table I). The differential $CD4^+$ and $CD8^+$ T cell distributions are particularly relevant in view of the uniform distribution of $CD3^+$ lymphocytes in these patients' muscles, and show that cytotoxic T cells are present preferentially in the endomysium of PM muscles.

By staining with anti-CD3 and anti-TCR β chain mAbs on serial sections, we demonstrated that the T lymphocytes in our PM patients' muscles express the α/β TCR. Recently, γ/δ TCR⁺ T cells were identified in a patient with a unique form of PM and their TCR molecular characteristics were described as well as the putative antigen discussed (14, 15). To our knowledge, however, the molecular characteristics of the α/β TCRs expressed by the muscle infiltrating T cells in PM have not been characterized previously. We studied the repertoire of rearranged TCR V genes in the T cells infiltrating muscles by the RNA-PCR, which allowed us to detect even of poorly repre-

Table II. TCR $V\alpha$ and β Families Expressed in Polymyositis, DMD, and Control Muscles

$V\alpha$ Family	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18			
PM patients	11	1	1	—	9	—	1	—	—	—	—	4	3	5	—	2	2	—			
Controls*	—	—	—	—	—	—	—	—	—	—	—	2	—	2	—	—	—	—			
DMD patients	2	1	1	—	2	—	1	—	—	—	1	2	1	—	—	1	1	—			
$V\beta$ Family	1	2	3	4	5.1	5.2	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20
PM patients	13	—	1	1	1	1	1	2	2	—	—	1	1	1	2	15	—	1	—	—	2
Controls*	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
DMD patients	1	4	3	3	3	3	4	4	4	3	—	2	1	3	3	2	—	1	—	1	1

* Controls: muscles from patients affected by muscular diseases other than inflammatory myopathy and dystrophies.




Figure 3. TCR amplifications and Southern blots of PM patients. V α 1 and V α 5 are shown in *A*. V β 1 and V β 15 in *B*. The upper panel is an EB-stained 2% NuSieve/Agarose (FMC Corp.) gel used for Southern analysis (*lower panel*); the hybridization was performed with α and β TCR internal probes and revealed by chemiluminescence.

sented TCR mRNAs. We verified that this procedure was able to amplify known V α and V β families from a mixed lymphocyte reactions (Fig. 2). The primers used in the PCR reactions have been used to specifically amplify TCR rearrangements from antigen-specific T cell clones (18). Using these primers, we detected specific TCR rearrangements in the muscle of PM and DMD patients, but not in patients with no dystrophy or inflammatory myopathies. The complete analysis of the TCR repertoire could be achieved with amounts as small as 10 mg of frozen muscle. Because the RNA-PCR technique is so sensitive in detecting TCR rearrangements, it could be used as a diagnostic help in PM cases where lymphocyte infiltration is not observed on routine histochemical or immunocytochemical analysis.

The TCR specificity of the PCR products was confirmed by hybridization with internal C α and C β probes on Southern blot, reamplification with V-V primers followed by unique site restriction analysis, and sequencing the PCR products. This analysis revealed a wide spectrum of TCR V gene rearrangements expressed on the infiltrating T cells of both PM and DMD patients (Table II). It is noteworthy to emphasize that in PM V α 1 is present in 73.3% of the patients examined, V α 5 in 60%, V β 1 in 86.6%, and V β 15 in all the patients. Differences in TCR frequencies between PM patients and controls (DMD and others) favor the supposition that these rearranged TCRs reflect T cell specificity of the cytotoxic damage in PM lesion.

T cells may home to inflammation sites as a result of superantigen activation or conventional antigen stimulation. These two possibilities may be distinguished at the molecular level: the presence of random D and J segments on the TCR indicates selection of superantigens (26), whereas the presence of a conserved sequence at the V-D-J junctions suggests that conventional antigen selection of the T lymphocytes is taking place (27).

To better understand T cell clonality at the inflammation sites we subcloned and sequenced the TCR V β 15 transcripts, since these were present in all our PM patients. Analysis of 10 colonies from two patients showed complete amino acid homology at the V β 15 region. Remarkably, rearrangements between V and J regions were skewed towards a preferential usage (9 out of 10) of J β 2.1. In the N-D-N region the D(or E)L motif




Figure 4. Unique restriction site analysis of V-V amplifications. The EB agarose gels with the uncut PCR amplification products and their digested fragments are shown; each gel is paired with the graphic map of the V-V restriction site analysis showing the size of the PCR amplification product and the relative digested fragments. Forward primers for V α 1, α 5, V β 1, and β 15 are described in reference 18; reverse primers for V α 1: 5'-ACAGAAGTACTCAGCTGTGTC-3', for V α 5: 5'-GGTAGCTGAGTCTGCAGGCTGGGA-3', for V β 1: 5'-GCTGGCACAGAAATACAAAGC-3', for V β 15: 5'-CTGGTGGCACAG-AAGTAAAGA-3'. Profile amplification: 95°C denaturation for 1 min, 55°C annealing for 1 min, 72°C extension for 1 min; 30 cycles.

was identified in 50% of the colonies examined. The CDR3 region contains TCR residues that are responsible for antigen binding, which confer T cell specificity. According to recent works (28, 29) the CDR3 region may reside between amino acids 93-106 on ATL21 (see Table III). Comparison of the CDR3 region sequences of our colonies indicates the presence of the common motif: D(or E)L-S-EQF. No random D or J segments were observed and our data favor an antigen selection of the T cells within the sites of inflammation. Our data could not show whether the relevant TCR V families were ascribable to CD8⁺ or CD4⁺ T lymphocytes preferentially, because RNA was extracted from the homogenate of whole muscle. Analysis of the TCR characteristics of CD8⁺ or CD4⁺ T cell clones derived from PM muscles would resolve this problem.

The TCR repertoire observed in DMD muscles revealed a wide range of α/β TCR families, but no dominant TCR V α or V β rearrangements were found. The presence of T lymphocytes in the context of muscle degeneration in DMD can be explained as nonspecific cell recruitment consequent on the inflammatory reactions accompanying muscle cell destruction. In PM a specific pathogenic antigen may trigger the T-

Table III. Alignment of TCR-V β 15 Amino Acid Sequences from Two PM Patients

V region		(N)D(N)	J region	C region
		93 ↓	CDR3 106 ↓	
V β 15 (ATL21)	SVSRQAQAKFSLSL S ESAIPNQTALYFCATS	DPGQ	SNQPQHFGDGR L SIL (J β 1.5)	EDLNN
Consensus		<u>DL</u> E	S <u>EQF</u>	
Patient n.1 col 1	SVSRQAQAKFSLSL S ESAIPNQTALYFCATS	<u>EL</u> GF	<u>EQ</u> FFGPGTR L TVL (J β 2.1)	EDLKN
col 2	SVSRQAQAKFSLSL S ESAIPNQTALYFCATS	<u>DL</u> D	<u>SY</u> <u>EQ</u> FFGPGTR L TVL (J β 2.1)	EDLKN
col 3	SVSRQAQAKFSLSL S ESAIPNQTALYFCATS	<u>DL</u> WD	<u>EQ</u> FFGPGTR L TVL (J β 2.1)	EDLKN
col 4	SVSRQAQAKFSLSL S LSAIPNQTALYFCATS	<u>EG</u> QES	<u>SY</u> NE <u>Q</u> FFGPGTR L TVL (J β 2.1)	EDLKN
col 5	SVSRQAQAKFSLSL S ESAIPNQTALYFCATS	<u>DL</u> N	<u>SY</u> Q <u>Q</u> FFGPGTR L TVL (J β 2.1)	EDLKN
col 6	SVSRQAQAKFSLSL S ESAIPNQTALYFCATS	GTSS	<u>EQ</u> FFGPGTR L TVL (J β 2.1)	EDLKN
col 7	SVSRQAQAKFSLSL S ALYFCATN	GTCS	<u>EQ</u> FFGPGTR L TVL (J β 2.1)	EDLKN
col 8	SVSRQAQAKFSLSL S LSAIPNQTALYFCATT	<u>DS</u> F G MV	<u>SY</u> NE <u>Q</u> FFGPGTR L TVL (J β 2.1)	EDLKN
Patient n.5 col 1	SVSRQAQAKFSLSL S ESAIPNQTALYFCATS	<u>V</u> <u>L</u> D	<u>SR</u> NE <u>Q</u> FFGPGTR L TVL (J β 2.1)	EDLKN
col 2	SVSRQAQAKFSLSL S ESAIPNQTALYFCAVS	<u>Q</u> Q <u>Q</u>	R <u>D</u> T <u>Q</u> YF <u>G</u> P <u>G</u> TR L TVL (J β 2.3)	EDLKN

Deduced amino acid sequences of the V β 15-D-J regions. Underlined characters identify residues in the CDR3 involved in the common motif. ATL21 aa sequence has been used to identify V-D-J boundaries and CDR3.

mediated immune reaction and this might not be the case in DMD. Moreover, expression of MHC antigens have been reported on muscle cells after IFN- γ treatment (30, 31) and it has been demonstrated that myoblasts might act as antigen presenting cells for antigen-specific T lymphocytes (32).

Over the last few years, the molecular analysis of T cell involvement in the animal model of autoimmunity such as experimental allergic encephalomyelitis has provided evidence for restricted TCR usage in the pathogenesis of the disease (33, 34). These observations led to the use of anti-TCR mAbs and vaccination with synthetic peptides of the CDR2 and CDR3 TCR regions; both proved beneficial in experimental allergic encephalomyelitis (33, 35). Limited TCR gene rearrangements have been found in lymphocytes infiltrating brains of multiple sclerosis patients (36), synovial tissues of rheumatoid arthritis patients (37), liver of primary biliary cirrhosis (38), and in the thyroid of thyroiditis patients (39). In multiple sclerosis plaques a dominant CDR3 sequence identical with that of TCR clones specific for myelin basic protein has been found (40). Probing the molecular characteristics of TCRs in combination with T cell function studies might lead to the identification of more selective immunosuppressive treatments in patients with these diseases (33, 41, 42). Currently nonspecific therapies like steroids or cytotoxic drugs (methotrexate) are given to treat PM. In particular the fact that V α 1, V α 5, V β 1, and V β 15 are expressed in a restricted manner in PM patients may be relevant for the development of new specific immunotherapies in this disease.

Our results show that the TCR repertoire of the T cells infiltrating muscle in PM is restricted. Finding nonrandomly rearranged V-D-J regions of the TCR may indicate that these lymphocytes have undergone positive muscle antigen selection. PM should be added to the list of diseases whose pathogenesis involves a restricted group of T cells.

Acknowledgments

The authors would like to thank Dr. L. Morandi and Dr. F. Dworzak for performing the muscle biopsies, and Mr. S. Daniel and Mrs. F. Blasevich for technical assistance.

This work has been partially funded by grants from the Italian Ministry of Health No. 9029/91 and by Telethon Italia to R. Mantegazza.

References

1. Banker, B. Q., and A. G. Engel. 1986. The polymyositis and dermatomyositis syndromes. In *Myology*. B. Q. Banker and A. G. Engel, editors. McGraw Hill Inc., New York. 1385-1422.
2. Mastaglia, F. L., and V. J. Ojeda. 1985. Inflammatory myopathies: part 1. *Ann. Neurol.* 17:215-227.
3. Mastaglia, F. L., and V. J. Ojeda. 1985. Inflammatory myopathies: part 2. *Ann. Neurol.* 17:317-323.
4. Iyer, V., A. R. Lawton, and G. M. Fenichel. 1983. T-cell subsets in polymyositis. *Ann. Neurol.* 13:452-453.
5. Arahata, K., and A. G. Engel. 1984. Monoclonal antibody analysis of mononuclear cells in myopathies. I. Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. *Ann. Neurol.* 16:193-208.
6. Engel, A. G., and K. Arahata. 1984. Monoclonal antibody analysis of mononuclear cells in myopathies. II. Phenotypes of autoinvasive cells in polymyositis and inclusion body myositis. *Ann. Neurol.* 16:209-215.
7. Arahata, K., and A. G. Engel. 1988. Monoclonal antibody analysis of mononuclear cells in myopathies. IV. Cell-mediated cytotoxicity and muscle fiber necrosis. *Ann. Neurol.* 23:168-173.
8. Arahata, K., and A. G. Engel. 1988. Monoclonal antibody analysis of mononuclear cells in myopathies. V. Identification and quantitation of T8⁺ cytotoxic and T8⁺ suppressor cells. *Ann. Neurol.* 23:493-499.
9. Appleyard, S. T., M. J. Dunn, V. Dubowitz, and M. L. Rose. 1985. Increased expression of HLA ABC class I antigens by muscle fibers in Duchenne muscular dystrophy, inflammatory myopathy and other neuromuscular disorders. *Lancet.* i:361-363.
10. McDuall, R. M., M. J. Dunn, and V. Dubowitz. 1989. Expression of class I and class II antigens in neuromuscular diseases. *J. Neurol. Sci.* 89:213-226.
11. Karpati, G., Y. Pouliot, and S. Carpenter. 1989. Expression of immunoreactive major histocompatibility complex products in human skeletal muscles. *Ann. Neurol.* 23:64-72.
12. Enslie-Smith, A., K. Arahata, and A. G. Engel. 1989. MHC class I antigen expression, immunolocalization of interferon subtypes and T cell-mediated cytotoxicity in myopathies. *Hum. Pathol.* 20:224-231.
13. Wolf, R. E., and B. A. Baethge. 1990. Interleukin-1 α , interleukin-2, and soluble Interleukin-2 receptors in polymyositis. *Arthritis Rheum.* 33:1001-1014.
14. Hohlfeld, R., A. G. Engel, K. Li, and M. C. Harper. 1991. Polymyositis mediated by T lymphocytes that express the γ/δ receptor. *N. Engl. J. Med.* 324:877-881.
15. Pluschke, G., D. Rügge, R. Hohlfeld, and A. G. Engel. 1992. Autoaggressive myocytotoxic T lymphocytes expressing an unusual γ/δ T cell receptor. *J. Exp. Med.* 176:1785-1789.
16. Dalakas, M. C. 1991. Polymyositis, dermatomyositis, and inclusion-body myositis. *N. Engl. J. Med.* 325:1487-1498.
17. Kawasaki, E. S. 1990. Amplification of RNA. In *PCR Protocols. A Guide*

- to Methods and Applications. M. A. Innis, D. H. Gelfand, J. J. Sninsky, and T. J. White, editors. Academic Press Inc., San Diego. 21–27.
18. Panzara, M. A., E. Gussoni, L. Steinman, and J. R. Oksenberg. 1992. Analysis of TCR repertoire using the polymerase chain reaction and specific oligonucleotide primers. *Biotechniques*. 12:728–735.
 19. Chomczynsky, P., and N. Sacchi. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. *Anal. Biochem.* 162:156–159.
 20. Sanger, F., S. Nicklen, and A. R. Coulson. 1977. DNA sequencing with chain terminating inhibitors. *Proc. Natl. Acad. Sci. USA.* 74:5463–5467.
 21. Kimura, N., B. Toyonaga, Y. Yoshikai, F. Triebel, P. Debre, M. D. Minden, and T. W. Mak. 1986. Sequences and diversity of human T cell receptor β chain variable region genes. *J. Exp. Med.* 164:739–750.
 22. Andretta, F., J. R. Oksenberg, P. Bernasconi, L. Morandi, F. Cornelio, L. Steinman, and R. Mantegazza. 1992. Restricted TCR $V\alpha\text{-}\beta$ gene rearrangements, perforin and granzyme A expression were analyzed in PM muscles. 8th International Congress of Immunology, Budapest, Hungary, August 23–28, 1992. 76:2. (Abstr.)
 23. Bernasconi, P., M. Gebbia, F. Andretta, F. Cornelio, and R. Mantegazza. 1992. Fibrogenic cytokine transcripts were observed within polymyositis and Duchenne muscular dystrophy muscles. 8th International Congress of Immunology, Budapest, Hungary, August 23–28, 1992. 688:5. (Abstr.)
 24. Leff, R. L., L. A. Love, F. W. Miller, S. J. Greenberg, E. A. Klein, M. C. Dalakas, and P. H. Plotz. 1992. Viruses in idiopathic inflammatory myopathies: absence of candidate viral genomes in muscle. *Lancet*. 339:1192–1195.
 25. Leon-Monzon, M., and M. C. Dalakas. 1992. Absence of persistent infection with enteroviruses in muscles of patients with inflammatory myopathies. *Ann. Neurol.* 32:219–222.
 26. Marrack, P., and J. Kappler. 1990. The staphylococcal enterotoxins and their relatives. *Science (Wash. DC)*. 248:705–711.
 27. Wucherpfennig, K. W., K. Ota, N. Endo, J. G. Seidman, A. Rosenzweig, H. L. Weiner, and D. A. Hafler. 1990. Shared human T cell receptor $V\beta$ usage to immunodominant regions of myelin basic protein. *Science (Wash. DC)*. 248:1016–1019.
 28. Chothia, C., D. R. Boswell, and A. M. Lesk. 1988. The outline structure of the T-cell $\alpha\beta$ receptor. *EMBO (Eur. Mol. Biol. Organ.) J.* 7:3745–3755.
 29. Jorgensen, J. L., U. Esser, B. Fazekas de St. Groth, P. A. Reay, and M. M. Davis. 1992. Mapping T-cell receptor-peptide contacts by variant peptide immunization of single-chain transgenics. *Nature (Lond.)*. 355:224–230.
 30. Mantegazza, R., S. M. Hughes, D. Mitchell, M. Travis, H. M. Blau, and L. Steinman. 1991. Modulation of MHC class II antigen expression in human myoblasts after treatment with IFN- γ . *Neurology*. 41:1128–1132.
 31. Hohlfeld, R., and A. G. Engel. 1990. Induction of HLA-DR expression on human myoblasts with interferon-gamma. *Am. J. Pathol.* 36:503–508.
 32. Goebels, N., D. Michaelis, H. Wekerle, and R. Hohlfeld. 1992. Human myoblasts as antigen-presenting cells. *J. Immunol.* 149:661–667.
 33. Acha-Orbea, H., D. Mitchell, L. Timmerman, D. Wraith, G. S. Tausch, M. K. Waldor, S. S. Zamvil, H. O. McDevitt, and L. Steinman. 1988. Limited heterogeneity of T cell receptors from lymphocytes mediating autoimmune encephalomyelitis allows specific immune intervention. *Cell*. 54:263–273.
 34. Urban, J. L., V. Kumar, V. H. Kono, C. Gomez, S. J. Horvath, J. Clayton, D. G. Ando, E. E. Sercarz, and L. Hood. 1988. Restricted use of T cell receptor V genes in murine autoimmune encephalomyelitis raises possibilities for antibody therapy. *Cell*. 54:577–592.
 35. Offner, H., G. A. Hashim, and A. A. Vandembark. 1991. T cell receptor peptide therapy triggers autoregulation of experimental encephalomyelitis. *Science (Wash. DC)*. 251:430–432.
 36. Oksenberg, J. R., S. Stuart, A. B. Begovich, R. B. Bell, H. A. Erlich, L. Steinman, and C. C. A. Bernard. 1990. Limited heterogeneity of rearranged T cell receptor V transcripts in brains of multiple sclerosis patients. *Nature (Lond.)*. 345:344–346.
 37. Williams, W. V., Q. Fang, D. Demarco, J. VonFeldt, R. B. Zurier, and D. B. Weiner. 1992. Restricted heterogeneity of T cell receptor transcripts in rheumatoid synovium. *J. Clin. Invest.* 90:326–333.
 38. Moebius, U., M. Manns, G. Hess, G. Kober, K. H. Meyer zum Buschenfelde, and S. C. Meuer. 1990. T cell receptor gene rearrangement of T lymphocytes infiltrating the liver in chronic active hepatitis B and primary biliary cirrhosis (PBC): oligoclonality of PBC-derived T cell clones. *Eur. J. Immunol.* 20:889–896.
 39. Davies, T. F., A. Martin, E. S. Concepcion, P. Graves, L. Cohen, and A. Ben-Nun. 1991. Evidence for limited variability of antigen receptors on intrathyroidal T cells in autoimmune thyroid disease. *N. Engl. J. Med.* 325:238–244.
 40. Oksenberg, J. R., M. A. Panzara, A. B. Begovich, D. Mitchell, E. A. Erlich, R. S. Murray, R. Shimonkevitz, M. Sherritt, J. Rothbard, C. C. A. Bernard, and L. Steinman. 1993. Selection for T cell receptor $V\beta\text{-D}\beta\text{-J}\beta$ gene rearrangements with specificity for myelin basic protein peptide in brain lesions of multiple sclerosis. *Nature (Lond.)* 362:68–70.
 41. Steinman, L., and R. Mantegazza. 1990. Prospects for specific immunotherapy in myasthenia gravis. *FASEB (Fed. Am. Soc. Exp. Biol.) J.* 4:2726–2731.
 42. Wraith, D., H. O. McDevitt, L. Steinman, and H. Acha-Orbea. 1989. T cell recognition as the target for immune intervention in autoimmune disease. *Cell*. 57:709–715.